Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.
1. A method of lowering glycated hemoglobin levels in a human subject having type 1 diabetes, the method comprising administering to the human subject 400 mg/day to 1200 mg/day of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof in combination with insulin or an insulin analog, wherein the {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof is orally administered one time a day, and wherein the incidence of hypoglycemic events in the human subject is reduced.
2. The method of claim 1 , wherein the glycated hemoglobin is HbA1c, and wherein the method comprises lowering HbA1c levels in the human subject by at least 0.3 percentage points.
3. The method of claim 1 , wherein the administering comprises administering the insulin or the insulin analog orally, subcutaneously, or by injection.
4. The method of claim 1 , wherein the {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof is administered in a solid dosage form.
5. The method of claim 4 , wherein the solid dosage form is a tablet or capsule.
6. The method of claim 4 , wherein the solid dosage form comprises 400-450 mg of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the glycated hemoglobin is HbA1c.
8. The method of claim 1 , wherein the insulin analog is a rapid-acting insulin, regular- or short-acting insulin, intermediate-acting insulin, a long-acting insulin, or a combination thereof.
9. The method of claim 1 , wherein the insulin analog comprises a short-acting insulin, intermediate-acting insulin, or a long-acting insulin.
10. The method of claim 9 , wherein the insulin analog comprises a combination of an intermediate-acting insulin and a long-acting insulin.
11. The method of claim 1 , wherein the insulin analog is insulin lispro, insulin aspart, insulin glulisine, isophane insulin, insulin zinc, insulin glargine, insulin detemir, or any combination thereof.
12. The method of claim 1 , wherein an insulin analog is administered, and the insulin analog is insulin lispro or insulin aspart.
13. The method of claim 1 , wherein the incidence of diabetic ketosis events in the human subject is reduced.